Walleye Capital
INFI

Walleye Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Walleye Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,700
Closed -$44 – 1565
2021
Q1 		$44 Buy
+13,700
New +$45.7K ﹤0.01% 1070

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GPC
Guardian Point Capital Charlottesville, Virginia $243M AUM 22.43% 1-Year Est. Return

Walleye Capital's INFI Position: Q2 2021 in Review

Walleye Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2021, closing a stake of 13,700 shares — an estimated $44 sold.

Walleye Capital first reported a position in INFI in Q1 2021 and held it in 1 quarter. The position peaked at $44 in Q1 2021. 97 funds tracked by Wall St. Rank hold INFI as of Q2 2021.

  • Walleye Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Walleye Capital sold 13,700 Infinity Pharmaceuticals, Inc. shares in Q2 2021, an estimated $44.
  • Walleye Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Walleye Capital's Infinity Pharmaceuticals, Inc. position peaked at $44 in Q1 2021.
  • 97 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.